PharmEasy Reports Financials for 2025

PharmEasy, a major player in e-pharmacy and diagnostics under API Holdings, revealed stagnant revenue in the fiscal year concluding in March 2025. Nonetheless, the Mumbai-based firm succeeded in cutting losses by 38%, primarily due to significant reductions in finance and depreciation expenditures throughout the previous fiscal year.

Financial Overview of PharmEasy

PharmEasy’s operating revenue saw a growth of 3.7%, reaching Rs 5,872 crore in FY25, compared to Rs 5,664 crore in FY24, as per the company’s financial records analyzed by Startup Superb. PharmEasy provides a variety of pharmaceutical products alongside diagnostic services and teleconsultations, all accessible via its mobile and web applications.

Approximately 87% of PharmEasy’s operating revenue, amounting to Rs 5,097.5 crore, originated from the sales of pharmaceutical and cosmetic items, while the remaining revenue stemmed from services like diagnostics, teleconsultations, delivery, warehousing, and commissions for facilitating pathological tests. Additionally, the company earned Rs 108 crore in non-operating income from interest and asset gains, bringing its total revenue to Rs 5,898 crore in FY25.

Cost Analysis

On the expenditure side, the cost of materials remained the largest expense, comprising 67.2% of total costs, amounting to Rs 4,844 crore in FY25. PharmEasy’s employee benefit expenditures increased by 30% to Rs 908.4 crore compared to Rs 700 crore in FY24. Simultaneously, finance costs were reduced by 30% to Rs 506 crore, while depreciation and amortisation expenses dropped by 21.7% to Rs 168.9 crore during the same period. Payments to delivery associates represented another substantial cost at Rs 90 crore. Additional expenses included legal, professional, sales promotion, and marketing costs. Overall, the company’s expenses remained flat at Rs 7,208.5 crore in FY25.

Loss Reduction and Profitability Measures

Despite the company’s revenue and expenses being relatively stable in FY25, a decrease in exceptional items, such as early redemption fees on non-convertible debentures and goodwill impairments, contributed to narrowing its losses by 38%, amounting to Rs 1,572.3 crore compared to Rs 2,533.5 crore in FY24. PharmEasy’s EBITDA loss was recorded at Rs 553.5 crore, with marginal improvements observed in ROCE and EBITDA margins to -13.9% and -15.71%, respectively. On a per-unit basis, PharmEasy spent Rs 1.23 to generate one rupee of revenue in the fiscal year ending March 2025.

Thyrocare Performance

Thyrocare, a diagnostic and preventative healthcare provider, which PharmEasy acquired a majority stake in June 2021, reported Rs 687.5 crore in FY25, marking a 20% increase from Rs 571.88 crore in FY24. During the same timeframe, its profits also rose by 30%, reaching Rs 90.75 crore.

Leadership Changes

Earlier in the year, the co-founders of PharmEasy, Dharmil Sheth, Dhaval Shah, and Hardik Dedhia, stepped back from their roles, with the fourth co-founder, Siddharth Shah, departing last month. API Holdings has appointed Rahul Guha, who is also the MD and CEO of Thyrocare, as the new MD and CEO of the parent entity.

Investment and Market Challenges

According to various sources from the startup data intelligence platform, PharmEasy has raised approximately $1.1 billion thus far from investors including Ranjan Pai’s MEMG, Prosus, and Temasek. Despite various challenges occurring post-acquisition, the significant downturn in the diagnostic sector following the Covid surge has greatly affected many companies that anticipated growth. Investors were hopeful for increased penetration in diagnostics, which has yet to materialise. Observations suggest that the hurdles are not over, especially considering the growing discontent surrounding practices in the healthcare industry. Issues such as private equity ownership of major hospital chains leading to increased costs, and patient distrust toward unnecessary diagnostic tests contribute to rising patient dissatisfaction. The probability of stringent government measures, including price caps, state subsidies, or regulations on online medication distribution, remains high in the near future, presenting significant challenges for companies like PharmEasy to navigate.